Myeloblastic Leukemia
Conditions
Keywords
Nk cells infusion, minimal residual disease in AML patients, trafficking of NK cells after infusion, cytolytic effects on leukemic cells
Brief summary
AML patients with de-novo or secondary disease with age greater than 18 years not eligible for stem cell transplantation for medical contraindications, lack of donor or lack of stem cells,are eligible. Leukemias other than AML and M3 FAB subtype will be excluded from the study. Immunosuppressive chemotherapy prior to NK cell infusion will include: fludarabine and cyclophosphamide 4g/m2 (Flu/Cy). The therapy will be administered over 6 days on inpatient basis. Haploidentical NK cells will be selected from a steady-state large volume leukapheresis product from a suitable KIR ligand incompatible donor. Donor-recipients pairs will be selected on the basis of known KIR ligands. In particular, haploidentical donors will be included if present at least one allele mismatch at a class I locus among the following ones: HLA-C alleles with Asn77-Lys80, HLA-C alleles with Ser77-Asn80, HLA-Bw4 alleles. Immunomagnetic enrichment of NK cells will follow two subsequent steps: 1) depletion of CD3+ T cells followed by 2) positive selection of CD56+ NK cells. Contaminating CD3+ T cells will be carefully evaluated.
Detailed description
When previously cryproserved NK cells are still available, further re-infusions may be performed, according to PI's evaluation. The number of remaining NK cells must be sufficient for the reinfusion of at least the minimum dose of cells (106/kg). At least two months should elapse between two consecutive infusion procedures.
Interventions
BIOLOGICALNK cells
NK cells infusion after immunosuppressive chemotherapy
Sponsors
University of Bologna
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent. * Performance Status ≥ 70% (Karnofsky score) or ≤ 2 (WHO). * Age greater than 18 years. * Availability of a KIR incompatible haploidentical donor. * Adequate renal (serum creatinine \< 2 mg/dl), pulmonary (Sat O2 ≥ 96%) and hepatic (ALT/AST \< 2.5 x N) function. * Patients enrolled in the protocol must have an autologous graft cryopreserved to be reinfused in case of severe myelosuppression induced by haploidentical NK cells. Back-up cells will be reinfused in case of ANC \< 0.5 x 109/L at day + 40 from the start of immunosuppressive regimen.
Exclusion criteria
* Age \< 18. * People unable to give informed consent. * HIV positivity. * HCV positivity with high viral load. * Intercurrent organ damage or medical problems that would interfere with therapy. * Pregnant or nursing females. * Current uncontrolled infection. * No availability of a cryopreserved autologous stem cell graft to be reinfused in case of severe myelosuppression. * Signs or symptoms of fluid retention (e.g. pleural effusion)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the feasibility of the selection and reinfusion of 5x10E6 haploidentical natural killer (NK) cells /Kg of body weight (target cell dose) in at least 40% of adult patients with active acute myeloblastic leukemia (AML) entering the study | every 6 months |
| To assess the feasibility of the reinfusion of the minimum accepted cell dose (1x10E6 haploidentical NK cells /Kg) in all patients enrolled into the protocol | every 6 months |
Secondary
| Measure | Time frame |
|---|---|
| To assess the percentage of patients entering complete remission (CR) after the reinfusion of highly purified haploidentical NK cells | every 6 months |
| To evaluate the microchimerism of AML patients receiving haploidentical human NK cells for adoptive immunotherapy | every 6 months |
| To assess the safety of infusion of haploidentical NK cells, following immunosuppressive chemotherapy, considered as the incidence of adverse event (graded according to WHO) and clinically significant abnormal laboratory values following reinfusion | every 6 months |
| To assess the disease-free and overall survival of AML patients infused with haploidentical NK cells | every 6 months |
| To evaluate, in vitro and in vivo, the antitumor activity of haploidentical NK cells infused in AML patients | every 6 months |
Countries
Italy
Contacts
Primary ContactRoberto M Lemoli, MD
Backup ContactAntonio Curti, MD
Outcome results
None listed